While Altimmune Inc has overperformed by 0.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALT fell by -45.28%, with highs and lows ranging from $11.16 to $5.14, whereas the simple moving average fell by -14.27% in the last 200 days.
On February 28, 2025, William Blair started tracking Altimmune Inc (NASDAQ: ALT) recommending Mkt Perform. A report published by Stifel on January 08, 2025, Initiated its previous ‘Buy’ rating for ALT. UBS also rated ALT shares as ‘Buy’, setting a target price of $26 on the company’s shares in an initiating report dated November 12, 2024. Goldman initiated its ‘Neutral’ rating for ALT, as published in its report on January 24, 2024. Goldman’s report from March 22, 2023 suggests a price prediction of $6 for ALT shares, giving the stock a ‘Neutral’ rating. Goldman also rated the stock as ‘Buy’.
Analysis of Altimmune Inc (ALT)
Further, the quarter-over-quarter decrease in sales is -86.49%, showing a negative trend in the upcoming months.
Altimmune Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -59.86% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 13.10, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and ALT has an average volume of 2.61M. On a monthly basis, the volatility of the stock is set at 7.63%, whereas on a weekly basis, it is put at 8.50%, with a gain of 9.44% over the past seven days. Furthermore, long-term investors anticipate a median target price of $22.38, showing growth from the present price of $5.97, which can serve as yet another indication of whether ALT is worth investing in or should be passed over.
How Do You Analyze Altimmune Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.04%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 53.06% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ALT shares are owned by institutional investors to the tune of 53.06% at present.
